GC treatment combined with dual inhibition of FLT3 and SFKs with our previously developed compound RK-20449 led to reduction of GC-resistant human leukaemia cells in the MLL-ALL engrafted mice. Here, KMT2A is linked to acute lymphoblastic leukemia.